Table 2 Characteristics of patients with mucormycosis and COVID-19 reported in the literature
Country (case) | Mean age | Sex | Underlying conditions | Type of Mucormycosis | Outcome |
|---|---|---|---|---|---|
India (n = 110) | 53.5 | M:86,F:24 | DM:88,DKA:9 CKD:9, RT:2 SOT:1,CGD:1 DCLD:1,TB:1 | Rhino-Facial: Majority Pulmonary:2.7% | Died:27,Alive:74 LFU:4, Unchanged:4 LAMA:5 |
Iran (n = 20) | 51.6 | M:11,F:9 | DM:15,HM:2 | Rhino-Facial | Died:8, Alive:12 |
Turkey (n = 12) | 64.5 | M:9,F:3 | DM:9 | ROM, ROCM | Died:8,Alive:4 |
Egypt (n = 11) | 53 | M:7,F:4 | DM:7 | ROCM | Died:5,Alive:6 |
USA (n = 10) | 51.4 | M:8,F:2 | DM:7 | ROCM:3,ROM:3 Pulmonary:4 | Died:8, Alive:2 |
The Netherlands (n = 4) | 60 | M:4 | DM:2, CLL:1 | ROCM, Pulmonary Disseminated | Died:3, Alive:1 |
UK (n = 2) | 22 | M:2 | Hypothyroidism:1 Obesity:1 | Disseminated | Died:2 |
Spain (n = 2) | 55 | M:2 | DM:1, RT:2 | Rhino-Facial, Musculoskeletal | Alive:2 |
Australia (n = 1) | 53 | M:1 | MDS, AML | Pulmonary | Died |
Brazil (n = 1) | 86 | M:1 | HTN | GIM | Died |
France (n = 1) | 55 | M:1 | FL, HCT | Pulmonary | Died |
Mexico (n = 1) | 24 | F:1 | DKA | ROM | Died |
Italy (n = 1) | 66 | M:1 | HTN | Pulmonary | Died |
Iraq (n = 1) | 53 | M:1 | DM | ROCM | Died |